Kiora Pharmaceuticals (KPRX)
(Delayed Data from NSDQ)
$3.15 USD
-0.09 (-2.78%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $3.15 0.00 (0.00%) 4:54 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
KPRX 3.15 -0.09(-2.78%)
Will KPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KPRX
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
KPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KPRX
Kiora Pharmaceuticals target ajusted to $54 from $6 at Ladenburg
Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress
Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024
Buy Rating Affirmed for Kiora Pharmaceuticals Amid Strategic Enhancements and Clinical Progress